U.S. Markets close in 5 hrs 15 mins

Integer Holdings Corporation Reports Third Quarter 2020 Results

  • Oops!
    Something went wrong.
    Please try again later.
Integer Holdings Corporation
·23 min read
  • Oops!
    Something went wrong.
    Please try again later.

~ Results in line with expectations, Strong cash flow from operations ~
~ Expect beginning of sales recovery and improved profitability in 4Q20 ~

PLANO, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and nine months ended October 2, 2020. Unless otherwise stated, all results and comparisons are from continuing operations.

Executing strategy through the COVID-19 pandemic

  • Throughout the pandemic, Integer associates continue to deliver critical products that customers and patients rely on every day.

  • Integer’s Manufacturing Excellence strategic imperative continues to deliver results during COVID-19.

  • Integer continues to invest in its product line and operational strategy to create long-term value, including manufacturing capabilities and R&D resources.

Third Quarter 2020 Highlights (compared to Third Quarter 2019)

  • The impact of COVID-19 on the third quarter 2020 financial results was consistent with Integer’s second quarter 2020 earnings communication.

  • Sales declined $68 million to $236 million, a decrease of 22%.

  • GAAP income was $30 million, a decrease of 1%. Non-GAAP adjusted income declined $23 million to $17 million, a decrease of 58%.

  • Adjusted EBITDA declined $33 million to $37 million, a decrease of 47%.

  • GAAP diluted EPS was $0.92 per share for both periods. Non-GAAP adjusted diluted EPS decreased $0.70 per share to $0.50 per share, a decrease of 58%.

  • Net total debt decreased $23 million from the end of the second quarter 2020 to $747 million.

  • The third quarter 2020 GAAP results include a pre-tax gain of $28 million, resulting in an after-tax impact of $0.67 per diluted share from a patent litigation judgment affirmed by the United States Court of Appeals in Integer’s favor, which are excluded from non-GAAP adjusted results.

  • On October 15, 2020 Integer received cash from the patent litigation judgment and paid down an additional $28 million of debt.

Fourth Quarter Outlook

  • Sales are projected to be $20 million to $35 million higher than the third quarter 2020.

  • Given the $28 million pre-tax patent litigation judgment gain in the third quarter 2020, GAAP operating income margin is expected to decline in the fourth quarter 2020.

  • Adjusted Operating Income margin is projected to be 200 to 300 basis points higher than the third quarter 2020.

“Our third quarter results demonstrate improved profitability versus the second quarter, and we expect the fourth quarter to be even stronger, as sales begin to recover from the pandemic and the profit margin rate recovery accelerates”, said Joseph Dziedzic, Integer’s president and chief executive officer. “Our Manufacturing Excellence strategic imperative continues to deliver strong operational and financial results. We remain focused on executing our strategy and making the necessary investments to be our customers’ partner of choice and deliver our financial objectives.”

Discussion of Product Line Third Quarter 2020 Sales (compared to Third Quarter 2019)

  • Cardio & Vascular sales decreased 16%. Sales were negatively impacted by the COVID-19 pandemic and a blend of our customers’ responses across nearly all C&V markets.

  • Cardiac & Neuromodulation sales decreased 32%. CRM and Neuromodulation declined commensurate with the COVID-19 pandemic impact and a blend of our customers’ responses. Additionally, the fourth quarter 2019 Nuvectra bankruptcy created a $3 million headwind.

  • Advanced Surgical, Orthopedics & Portable Medical includes sales to the acquirer of our AS&O product line, Viant, under supply agreements entered into as part of the divestiture. Sales declined 12% driven by the COVID-19 pandemic impact and a blend of our customers’ responses. Portable Medical remained stable while Orthopedics and Advanced Surgical declined.

  • Electrochem sales declined 42% driven by a severe decline in the energy market and demand fall-out from the COVID-19 pandemic.

Summary of Financial and Product Line Results from Continuing Operations

(dollars in thousands, except per share data)

Three Months Ended

GAAP

October 2,
2020

September 27,
2019

Change

Organic
Change(a)

Medical Sales

Cardio & Vascular

$

124,596

$

148,581

(16.1

)

%

(18.0

)

%

Cardiac & Neuromodulation

72,909

106,533

(31.6

)

%

(31.6

)

%

Advanced Surgical, Orthopedics & Portable Medical

30,179

34,310

(12.0

)

%

(12.2

)

%

Total Medical Sales

227,684

289,424

(21.3

)

%

(22.3

)

%

Non-Medical Sales

8,258

14,163

(41.7

)

%

(41.7

)

%

Total Sales

$

235,942

$

303,587

(22.3

)

%

(23.2

)

%

Income from continuing operations

$

30,342

$

30,586

(0.8

)

%

(55.6

)

%

Diluted EPS from continuing operations

$

0.92

$

0.92

%

(55.5

)

%

Nine Months Ended

GAAP

October 2,
2020

September 27,
2019

Change

Organic
Change(a)

Medical Sales

Cardio & Vascular

$

432,885

$

451,552

(4.1

)

%

(5.3

)

%

Cardiac & Neuromodulation

252,404

337,932

(25.3

)

%

(25.3

)

%

Advanced Surgical, Orthopedics & Portable Medical

92,041

98,544

(6.6

)

%

(6.6

)

%

Total Medical Sales

777,330

888,028

(12.5

)

%

(13.1

)

%

Non-Medical Sales

27,153

44,429

(38.9

)

%

(38.9

)

%

Total Sales

$

804,483

$

932,457

(13.7

)

%

(14.3

)

%

Income from continuing operations

$

61,831

$

80,174

(22.9

)

%

(39.6

)

%

Diluted EPS from continuing operations

$

1.87

$

2.43

(23.0

)

%

(39.6

)

%

(a)

Organic Change is a Non-GAAP measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table C and Table D at the end of this release for a reconciliation of these amounts.


Three Months Ended

Non-GAAP(a)

October 2,
2020

September 27,
2019

Change

Organic
Change(b)

Adjusted EBITDA from continuing operations

$

36,508

$

69,444

(47.4

)

%

(45.9

)

%

Adjusted income from continuing operations

$

16,656

$

39,575

(57.9

)

%

(55.6

)

%

Adjusted diluted EPS from continuing operations

$

0.50

$

1.20

(58.3

)

%

(55.5

)

%

Nine Months Ended

Non-GAAP(a)

October 2,
2020

September 27,
2019

YTD
Change

Organic
Change(b)

Adjusted EBITDA from continuing operations

$

140,380

$

210,497

(33.3

)

%

(33.6

)

%

Adjusted income from continuing operations

$

68,425

$

113,047

(39.5

)

%

(39.6

)

%

Adjusted diluted EPS from continuing operations

$

2.07

$

3.42

(39.5

)

%

(39.6

)

%


(a)

Refer to Tables A and B at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

(b)

Organic Change for Adjusted EBITDA from continuing operations, Adjusted income from continuing operations, and Adjusted diluted EPS from continuing operations are Non-GAAP measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.

Conference Call Information
The Company will host a conference call on Thursday, October 29, 2020, at 9:00 a.m. EDT / 8:00 a.m. CDT to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (833) 714-0898 (U.S.) or (778) 560-2691 (outside U.S.) and the conference ID is 6778607. The call will be archived on the Company’s website. An earnings call slide presentation containing supplemental information about the Company’s results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.

About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

Contact Information
Tony Borowicz
SVP, Strategy, Business Development & Investor Relations
716.759.5809
tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information

In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted income, adjusted diluted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted operating income, adjusted operating income margin, adjusted EBITDA, adjusted EBITDA margin, and organic change rates, all from continuing operations. Adjusted income and adjusted diluted EPS from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) (gain) loss on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal provision for the period. Adjusted diluted EPS from continuing operations is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding. EBITDA from continuing operations is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure. Adjusted EBITDA from continuing operations consists of EBITDA from continuing operations plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi).

Adjusted operating income from continuing operations consists of GAAP operating income adjusted for the same items listed above except for items (viii), (ix), (x) and (xi). Adjusted operating income margin is adjusted operating income as a percentage of sales, all from continuing operations.

Adjusted EBITDA margin is adjusted EBITDA as a percentage of sales, all from continuing operations. Organic sales change is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired or divested during the period from the current/previous period amounts, respectively.

Organic change rates for adjusted EBITDA from continuing operations, adjusted income from continuing operations and adjusted diluted EPS from continuing operations exclude the impact of foreign currency exchange gains and losses included in other (income) loss, net, and the contribution of acquisitions. Contribution of acquisitions represents results, based on the growth rate being presented, attributable to acquired entities for the first four full quarters plus any partial period since the entities' acquisition date. After the completion of four full fiscal quarters, results of the acquired entity are treated as organic for current and comparable historical periods.

We believe that the presentation of adjusted income, adjusted diluted EPS, EBITDA, adjusted EBITDA, adjusted EBITDA margin, and organic change rates, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.

Forward-Looking Statements

Some of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: the duration, scope and impact of the COVID-19 pandemic, including government, social, business and other actions taken in response to the pandemic and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our ability to respond to changes in technology; the intense competition we face and our ability to successfully market our products; our ability to develop new products and expand into new geographic and product markets; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability claims; our ability to protect our intellectual property and proprietary rights; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; our ability to integrate acquisitions and operate acquired businesses in accordance with expectations; our dependence upon our senior management team and technical personnel; our ability to realize the benefits from cost savings and consolidation initiatives; interruptions in our manufacturing operations; our ability to comply with environmental regulations; our complex international tax profile; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; market, financial and other risks related to our international operations and sales; global economic factors, including currency exchange rates and interest rates; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

Condensed Consolidated Balance Sheets - Unaudited

(in thousands)

October 2,
2020

December 31,
2019

ASSETS

Current assets:

Cash and cash equivalents

$

99,943

$

13,535

Accounts receivable, net

151,201

191,985

Inventories

156,858

167,256

Contract assets

39,593

24,767

Refundable income taxes

6,521

Prepaid expenses and other current assets

44,537

17,852

Total current assets

498,653

415,395

Property, plant and equipment, net

249,982

246,185

Goodwill

851,679

839,617

Other intangible assets, net

759,419

775,784

Deferred income taxes

5,223

4,438

Operating lease assets

46,083

42,379

Other long-term assets

37,956

29,295

Total assets

$

2,448,995

$

2,353,093

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Current portion of long-term debt

$

37,500

$

37,500

Accounts payable

55,397

64,975

Income taxes payable

1,068

3,023

Current portion of lease liabilities

8,287

7,507

Accrued expenses and other current liabilities

51,208

66,073

Total current liabilities

153,460

179,078

Long-term debt

801,607

777,272

Deferred income taxes

188,788

187,978

Operating lease liabilities

39,030

37,114

Other long-term liabilities

33,113

19,163

Total liabilities

1,215,998

1,200,605

Stockholders’ equity:

Common stock

33

33

Additional paid-in capital

698,654

701,018

Treasury stock

(8,809

)

Retained earnings

502,089

440,258

Accumulated other comprehensive income

32,221

19,988

Total stockholders’ equity

1,232,997

1,152,488

Total liabilities and stockholders’ equity

$

2,448,995

$

2,353,093


Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except per share data)

Three Months Ended

Nine Months Ended

October 2,
2020

September 27,
2019

October 2,
2020

September 27,
2019

Sales

$

235,942

$

303,587

$

804,483

$

932,457

Cost of sales

178,009

210,201

591,985

653,477

Gross profit

57,933

93,386

212,498

278,980

Operating expenses:

Selling, general and administrative expenses (SG&A)(a)

3,609

32,935

73,969

101,034

Research, development and engineering costs (RD&E)

11,892

11,729

37,879

34,720

Other operating expenses (OOE)

2,674

2,241

7,631

8,239

Total operating expenses

18,175

46,905

119,479

143,993

Operating income

39,758

46,481

93,019

134,987

Interest expense, net

9,368

12,337

29,002

39,779

(Gain) loss on equity investments, net

(2,234

)

(986

)

(3,954

)

666

Other (income) loss, net

1,224

(369

)

(233

)

(921

)

Income from continuing operations before taxes

31,400

35,499

68,204

95,463

Provision for income taxes

1,058

4,913

6,373

15,289

Income from continuing operations

$

30,342

$

30,586

$

61,831

$

80,174

Discontinued operations:

Income from discontinued operations before taxes

5,316

Provision for income taxes

178

Income from discontinued operations

$

$

$

$

5,138

Net income

$

30,342

$

30,586

$

61,831

$

85,312

Basic earnings per share:

Income from continuing operations

$

0.92

$

0.94

$

1.88

$

2.46

Income from discontinued operations

$

$

$

$

0.16

Basic earnings per share

$

0.92

$

0.94

$

1.88

$

2.62

Diluted earnings per share:

Income from continuing operations

$

0.92

$

0.92

$

1.87

$

2.43

Income from discontinued operations

$

$

$

$

0.16

Diluted earnings per share

$

0.92

$

0.92

$

1.87

$

2.58

Weighted average shares outstanding:

Basic

32,859

32,660

32,833

32,606

Diluted

33,076

33,068

33,107

33,019


(a)

Selling, general and administrative expenses for the three and nine months ended October 2, 2020 includes a net gain of $28.2 million recorded during the third quarter of 2020 in connection with the resolution of the AVX Corporation patent litigation matter.


Condensed Consolidated Statements of Cash Flows(a) - Unaudited

(in thousands)

Nine Months Ended

October 2,
2020

September 27,
2019

Cash flows from operating activities:

Net income

$

61,831

$

85,312

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

59,005

57,397

Debt related charges included in interest expense

3,145

5,280

Stock-based compensation

6,229

6,894

Non-cash charges related to customer bankruptcy

562

Non-cash lease expense

5,824

5,555

Non-cash (gain) loss on equity investments

(3,954

)

666

Other non-cash gains

(184

)

(1,088

)

Deferred income taxes

42

(1,086

)

Gain on sale of discontinued operations

(4,974

)

Changes in operating assets and liabilities, net of acquisition:

Accounts receivable

42,096

(29,962

)

Inventories

10,272

(8,567

)

Contract assets, prepaid expenses and other assets

(47,350

)

(16,384

)

Accounts payable

(5,152

)

17,760

Accrued expenses and other liabilities

(13,780

)

(8,988

)

Income taxes payable

(8,347

)

4,162

Net cash provided by operating activities

110,239

111,977

Cash flows from investing activities:

Acquisition of property, plant and equipment

(35,182

)

(24,704

)

Purchase of intangible asset

(4,607

)

Proceeds from sale of property, plant and equipment

76

5

Purchase of equity investments

(417

)

Acquisitions, net

(5,219

)

Proceeds from sale of discontinued operations

4,734

Net cash used in investing activities

(44,932

)

(20,382

)

Cash flows from financing activities:

Principal payments of long-term debt

(28,125

)

(97,125

)

Proceeds from senior secured revolving line of credit

185,000

20,000

Payments of senior secured revolving line of credit

(135,000

)

(25,000

)

Proceeds from the exercise of stock options

3,123

2,654

Payment of debt issuance costs

(431

)

Tax withholdings related to net share settlements of restricted stock unit awards

(2,869

)

(2,961

)

Net cash provided by (used in) financing activities

21,698

(102,432

)

Effect of foreign currency exchange rates on cash and cash equivalents

(597

)

(13

)

Net increase (decrease) in cash and cash equivalents

86,408

(10,850

)

Cash and cash equivalents, beginning of period

13,535

25,569

Cash and cash equivalents, end of period

$

99,943

$

14,719


(a)

Condensed Consolidated Statements of Cash Flows - Unaudited includes cash flows related to discontinued operations.

Reconciliations of Non-GAAP Measures from Continuing Operations

Table A: Income from Continuing Operations and Diluted EPS Reconciliations
(in thousands, except per share amounts)

Three Months Ended

October 2, 2020

September 27, 2019

Pre-Tax

Net of Tax

Per
Diluted
Share

Pre-Tax

Net of
Tax

Per
Diluted
Share

Income from continuing operations (GAAP)

$

31,400

$

30,342

$

0.92

$

35,499

$

30,586

$

0.92

Adjustments(a):

Amortization of intangibles

10,299

8,145

0.25

9,782

7,750

0.23

Certain legal expenses (gains) (SG&A)(b)

(27,959

)

(22,089

)

(0.67

)

99

78

Other operating expenses (OOE)(c)

2,674

2,070

0.06

2,241

1,710

0.05

Gain on equity investments, net

(2,234

)

(1,764

)

(0.05

)

(986

)

(779

)

(0.02

)

Loss on extinguishment of debt

291

230

0.01

Customer bankruptcy(d)

341

269

0.01

Tax adjustments

(317

)

(0.01

)

Adjusted income from continuing operations (Non-GAAP)

$

14,521

$

16,656

$

0.50

$

46,926

$

39,575

$

1.20

Weighted average shares for adjusted diluted EPS

33,076

33,068

Nine Months Ended

October 2, 2020

September 27, 2019

Pre-Tax

Net of Tax

Per
Diluted
Share

Pre-Tax

Net of
Tax

Per
Diluted
Share

Income from continuing operations (GAAP)

$

68,204

$

61,831

$

1.87

$

95,463

$

80,174

$

2.43

Adjustments(a):

Amortization of intangibles

30,894

24,425

0.74

29,467

23,324

0.71

Certain legal expenses (gains) (SG&A)(b)

(26,950

)

(21,291

)

(0.64

)

2,175

1,718

0.05

Other operating expenses (OOE)(c)

7,631

5,942

0.18

8,239

6,306

0.19

(Gain) loss on equity investments, net

(3,954

)

(3,123

)

(0.09

)

666

526

0.02

Loss on extinguishment of debt

1,265

999

0.03

Customer bankruptcy(d)

1,213

958

0.03

Tax adjustments

(317

)

(0.01

)

Adjusted income from continuing operations (Non-GAAP)

$

77,038

$

68,425

$

2.07

$

137,275

$

113,047

$

3.42

Weighted average shares for adjusted diluted EPS

33,107

33,019


(a)

The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b)

Represents the net gain of $28.2 million recorded during the third quarter of 2020 in connection with the resolution of the AVX Corporation patent litigation matter, as well as expenses associated with non-ordinary course legal matters.

(c)

Other operating expenses includes acquisition and integration related expenses, facility consolidation, optimization, manufacturing transfer and system integration charges, asset write-down and disposition charges, charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items.

(d)

In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). During the first nine months of 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales in our condensed consolidated statement of operations.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.

Table B: EBITDA Reconciliations
(in thousands)

Three Months Ended

Nine Months Ended

October 2,
2020

September 27,
2019

October 2,
2020

September 27,
2019

Income from continuing operations (GAAP)

$

30,342

$

30,586

$

61,831

$

80,174

Interest expense

9,368

12,337

29,002

39,779

Provision for income taxes

1,058

4,913

6,373

15,289

Depreciation

9,632

9,080

28,111

27,930

Amortization of intangibles

10,299

9,782

30,894

29,467

EBITDA from continuing operations (Non-GAAP)

60,699

66,698

156,211

192,639

Stock-based compensation (excluding OOE)

2,987

1,392

6,229

6,778

Certain legal expenses (gains)

(27,959

)

99

(26,950

)

2,175

Other operating expenses (OOE)

2,674

2,241

7,631

8,239

(Gain) loss on equity investments, net

(2,234

)

(986

)

(3,954

)

666

Customer bankruptcy

341

1,213

Adjusted EBITDA from continuing operations (Non-GAAP)

$

36,508

$

69,444

$

140,380

$

210,497

Total Sales

$

235,942

$

303,587

$

804,483

$

932,457

Adjusted EBITDA margin

15.5

%

22.9

%

17.4

%

22.6

%

Table C: Organic Sales from Continuing Operations Growth Rate Reconciliation (% Change)

GAAP
Reported
Growth

Impact of
Acquisitions
and Foreign
Currency(a)

Non-GAAP
Organic
Change

QTD Change (3Q 2020 vs. 3Q 2019)

Medical Sales

Cardio & Vascular

(16.1)%

(1.9)%

(18.0)%

Cardiac & Neuromodulation

(31.6)%

(31.6)%

Advanced Surgical, Orthopedics & Portable Medical

(12.0)%

(0.2)%

(12.2)%

Total Medical Sales

(21.3)%

(1.0)%

(22.3)%

Non-Medical Sales

(41.7)%

(41.7)%

Total Sales

(22.3)%

(0.9)%

(23.2)%

YTD Change (9M 2020 vs. 9M 2019)

Medical Sales

Cardio & Vascular

(4.1)%

(1.2)%

(5.3)%

Cardiac & Neuromodulation

(25.3)%

(25.3)%

Advanced Surgical, Orthopedics & Portable Medical

(6.6)%

—%

(6.6)%

Total Medical Sales

(12.5)%

(0.6)%

(13.1)%

Non-Medical Sales

(38.9)%

(38.9)%

Total Sales

(13.7)%

(0.6)%

(14.3)%


(a)

2020 sales have been adjusted to exclude the contribution of business acquisitions and foreign currency exchange rate fluctuations. 2019 sales have been adjusted to exclude the impact of foreign currency exchange rate fluctuations. There was no impact from business acquisitions on the 2019 periods.

Table D: Non-GAAP Organic Growth Rate Reconciliation (% Change)

GAAP
Reported
Growth(a)

Impact of
Non-GAAP
Adjustments(b)

Impact of
Acquisitions
and Foreign
Currency(c)

Non-GAAP
Organic
Change

QTD Change (3Q 2020 vs. 3Q 2019)

EBITDA from continuing operations

(9.0)%

(38.4)%

1.5%

(45.9)%

Income from continuing operations

(0.8)%

(57.1)%

2.3%

(55.6)%

Diluted EPS from continuing operations

—%

(58.3)%

2.8%

(55.5)%

YTD Change (9M 2020 vs. 9M 2019)

EBITDA from continuing operations

(18.9)%

(14.4)%

(0.3)%

(33.6)%

Income from continuing operations

(22.9)%

(16.6)%

(0.1)%

(39.6)%

Diluted EPS from continuing operations

(23.0)%

(16.5)%

(0.1)%

(39.6)%


(a)

EBITDA from continuing operations is a non-GAAP financial measure. See Table B for a reconciliation to the most comparable GAAP measure.

(b)

Represents the impact to our growth rate from our Non-GAAP adjustments. See Tables A and B for further detail on these items.

(c)

Represents the impact to our growth rate due to changes in foreign currency exchange rates realized in income and reported in other (income) loss, net in the consolidated statements of operations, and the adjustment to exclude the contribution of acquisitions when applicable.